Somnomed Limited · ASX:SOM
Somnomed — Investor Presentation (August 2012)
16 slides from Somnomed's investor presentation, Aug 31, 2012
Slide 1: Investor Presentation FY 2011 - 2012
For personal use only INVESTOR PRESENTATION FY 2011 - 2012 Dr Peter Neustadt (Executive Chairman) Mr Neil Verdal-Austin (CFO) This presentation contains forward-looking statements that involve risks and uncertainties. These forward-looking statements are not guarantees of SomnoMed's future performan
Slide 2: Disclaimer & Regulatory Disclosure
DISCLAIMER & REGULATORY DISCLOSURE For personal use only This document has been prepared as a summary only, and does not contain all information about the Company’s assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company’s
Slide 3: Key topics
Key topics For personal use only 1 Financial highlights 2 Financials 3 The future 4 Guidance and Milestones Summary years ahead and main and Cash Flow and strategic achievements direction © SomnoMed 2012 3
Slide 4: FY 2011/12 Financial Highlights
FY 2011/12 Financial Highlights For personal use only Sales revenue SomnoDent® MAS Gross Regional Sales, Group operating EBITDA Apnea unit Margin Marketing, profit before + 23% to sales improved to Admin & Corporate, + 9% to A$15.24m 70% Regulatory Research and A$1.082m (+28% to + 23% to Expense Dev
Slide 5: Main Achievements 2011/12
Main Achievements 2011/12 For personal use only Stated Guidelines Result Other Main Achievements | Record sales in all regions Volume MAS 32,000 30,878 (-3.5%) | Acquisition of Goedegebuure Slaaptechniek BV +23% Revenues +25% (+28% constant exchange rates) | Registration of SomnoDent® as reimbursabl
Slide 6: SomnoMed Progress in Revenue and Gross Margin
SomnoMed Progress in Revenue and Gross Margin For personal use only $30,000 Gross Margin Revenues $25,000 CAGR Revenue 43% Group GM grown from $20,000 44% in FY06 to 68% in FY12 $15,246 $A'000 $15,000 $12,335 $10,714 $10,000 $7,737 $5,000 $10,357 $3,658 $8,176 $6,084 $1,786 $2,273 $4,059 $801 $1,002
Slide 7: Continuing strong quarterly growth linked to increased MAS Margin to 70%
Continuing strong quarterly growth linked to increased MAS Margin to 70% For personal use only Units sold per quarter Growth in MAS Margin 9000 Total 80% 8000 CAGR Units 53% 70% 7000 60% 6000 50% 5000 4000 40% MAS Margin 3000 30% 2000 20% 1000 10% 0 0% Jun-08 Sep-08 Jun-09 Sep-09 Jun-10 Sep-10 Jun-1
Slide 8: Global Coverage Expanding
Global Coverage Expanding For personal use only Steady regional distribution Global Expansion Regional Unit Sales Mix 70% 60% 50% 2011/12 North Europe APAC 40% 2010/11 America Switzerland * France * Australia * Germany * (2012/13) New Zealand USA * 30% Austria Belgium Singapore * Canada (2012/13) It
Slide 9: Financial Summary Results
Financial Summary Results For personal use only Financial Summary ($000's) 11/12 10/11 09/10 08/09 07/08 06/07 Units 30,878 25,119 19,543 12,254 7,033 3,503 Revenue 15,246 12,335 10,714 7,737 3,658 2,273 Gross Margin 10,357 8,176 6,084 4,059 1,956 1,002 Operating profit (loss) before corporate, busi
Slide 10: EBITDA
EBITDA For personal use only $35,000 Revenue Gross Margin Operating Profit Before Corporate EBITDA $30,000 $1,082 $3,280 $25,000 $991 $3,061 $20,000 $10,357 $270 $1,897 $8,176 $A'000 $15,000 $6,084 $18 $10,000 $4,059 $15,246 $10,714 $12,335 $5,000 $7,737 $0 ($1,520) ($5,000) 2009 2010 2011 2012 © So
Slide 11: Cash Flow
Cash Flow For personal use only CONSOLIDATED CASH FLOW 2012 2011 SomnoMed Limited ( $000's) Cash from OPERATING ACTIVITIES 290 173 Cash generated from operations Payments for fixed assets (270) (481) * Improved and remains positive – now $290k vs $173k although effected by $1.5m increase in debtors
Slide 12: Positive Outlook for the Years Ahead: Current Business Model
Positive Outlook for the Years Ahead: For personal use only Current Business Model to generate 20-25% volume growth per annum with the following key drivers : | Continuing growth through home sleep tests, increasing number of dentists joining the SomnoMed Preferred Dentist network and increasing acc
Slide 13: Positive Outlook for the Years Ahead: Expanded Business Model
Positive Outlook for the Years Ahead For personal use only EXPANDED BUSINESS MODEL TO INCREASE REFERRALS FROM MEDICAL PRACTITIONERS AND ACCELERATE GROWTH TO 35%+ PER ANNUM OBJECTIVE 1. Increase acceptance of OAT by medical specialists 2. Position SomnoDent® products as the product of choice (a) Clin
Slide 14: Future Business Outlook
Future Business Outlook For personal use only 110,000 Future Dental Unit Forecast Future Future Medical and Dental Unit Forecast 100,000 100,000 90,000 Implementation of medical 80,000 expansion 72,000 Apnea Units strategy 2012-2013 70,000 75,000 60,000 History 53,000 60,000 50,000 48,000 40,000 40,
Slide 15: Milestones 2012/13
Milestones 2012/13 For personal use only | SomnoDent Apnea unit sales 38,000 to 40,000 units | SomnoMed Group Revenues to grow to $18 – 20 million | Appointment of key executives, staff and implementation of medical expansion program | Broad launch of SomnoDent® G2 in all SomnoMed markets | Distribu
Slide 16: Contacts
For personal use only contacts… EXECUTIVE CHAIRMAN | DR PETER NEUSTADT CHIEF FINANCIAL OFFICER | MR NEIL VERDAL–AUSTIN ADDRESS | LEVEL 3, 20 CLARKE STREET CROWS NEST NSW 2065 AUSTRALIA TELEPHONE | +61 (2) 9467 0400 WEBSITE | WWW.SOMNOMED.COM.AU